Abstracts tagged "T cells and spondylarthropathy"

Abstract Number: 2069 • 2018 ACR/ARHP Annual Meeting
The Epigenetic Regulator Sirtuin-1 Modulates T-Helper 17 Cell Differentiation in Axial Spondyloarthritis
Sarah Unterberger¹, Patrizia Fasching², Elisabeth Fliesser¹, Angelika Lackner³, Christian Dejaco², Winfried Graninger³, Martin Stradner² and Johannes Fessler^4,5, ¹Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Dep. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁵Department of Neurology, Harvard Medical School, Boston, MA
Background/Purpose: The NAD+ -dependent protein/histone deacetylase Sirtuin 1 (SIRT1) acts as an epigenetic regulator and has recently been reported to be involved in the development…
Abstract Number: 2318 • 2012 ACR/ARHP Annual Meeting
Reduced Thymus Function and Accelerated T-Cell Aging in Patients with Axial Spondylarthritis
Christian Dejaco¹, Wolfgang Schwinger², Andrea Raicht², Rusmir Husic³, Johannes Fessler³, Christoph G. Ammann⁴, Christina Duftner⁵, Winfried B. Graninger⁶ and Michael Schirmer⁷, ¹Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Division of Pediatric Hemato-Oncology, Medical University Graz, Graz, Austria, ³Rheumatology, Medical University Graz, Graz, Austria, ⁴Internal medicine, Medical Uiversity Innsbruck, Innsbruck, Austria, ⁵Internal Medicine, Hopital Kufstein, Kufstein, Austria, ⁶Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁷Internal medicine, Innsbruck Medical University, Innsbruck, Austria
Background/Purpose: To investigate thymic T-cell output, senescence of circulating T-cell subsets and changes of T cell subsets in patients with axial spondylarthritis (aSpA). Results are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].